ArticlePreventive medicine2017
Primary HPV testing recommendations of US providers, 2015.
Article in Preventive medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- A pragmatic randomized trial to compare strategies for implementing primary HPV testing for routine cervical cancer screening in a large healthcare system.Implementation science : IS · 2025Trial
- Clinician acceptability of self-collected human papillomavirus swabs as a primary cervical cancer screening method.Canadian family physician Medecin de famille canadien · 2022Article
- Awareness and Support of Clinician- and Patient-Collected Human Papillomavirus Testing for Cervical Cancer Screening Among Primary Care Clinicians.Women's health reports (New Rochelle, N.Y.) · 2022Article
- Obstetrician-gynecologists' practice patterns regarding HPV testing in cervical cancer screening in Turkey.Turkish journal of obstetrics and gynecology · 2021Article
- Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021Article
- Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results.Journal of lower genital tract disease · 2020Article
- Rate of detecting CIN3+ among patients with ASC-US using digital colposcopy and dynamic spectral imaging.Oncology letters · 2020Article
- Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.Journal of the National Cancer Institute · 2019Article
- Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women.BMC women's health · 2018Article
- The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?Journal of lower genital tract disease · 2018Article
- Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United States.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the HPV testing recommendations of US physicians who perform cervical cancer screening.
methodsData from the 2015 DocStyles survey of U.S. health care providers were analyzed using multivariate logistic regression to identify provider characteristics associated with routine recommendation of primary HPV testing for average-risk, asymptomatic women ≥30years old. The analysis was limited to primary care physicians and obstetrician-gynecologists who performed cervical cancer screening (N=843).
resultsPrimary HPV testing for average-risk, asymptomatic women ≥30years old was recommended by 40.8% of physicians who performed cervical cancer screening, and 90.1% of these providers recommended primary HPV testing for women of all ages. The screening intervals most commonly recommended for primary HPV testing with average-risk, asymptomatic women ≥30years old were every 3years (35.5%) and annually (30.2%). Physicians who reported that patient HPV vaccination status influenced their cervical cancer screening practices were almost four times more likely to recommend primary HPV testing for average-risk, asymptomatic women ≥30years old than other providers (Adj OR=3.96, 95% CI=2.82-5.57).
conclusionMany US physicians recommended primary HPV testing for women of all ages, contrary to guidelines which limit this screening approach to women ≥25years old. The association between provider recommendation of primary HPV testing and patient HPV vaccination status may be due to anticipated reductions in the most oncogenic HPV types among vaccinated women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.